side effects of tirzepatide and semaglutide caused roughly half as many patients to stop treatment because gastrointestinal as semaglutide. In the first major head-to-head obesity trial, GI side effects caused treatment discontinuation in: Tirzepatide Comparative safety and side effects

2023;46:S1267

What the Research Says The bottom line: No randomized controlled trial has tested weekly tirzepatide doses below 2.5 mg for weight loss, cardiovascular benefit, or metabolic outcomes

Semaglutide reduced ELF score and VCTE-measured liver stiffness, and improved N-terminal type III collagen propeptide (PRO-C3) and the FibroScan-AST (FAST) score, markers associated with fibrotic activity and risk stratification in MASLD [7,13,14]

Embrace a Nutrition Plan for Sustainable Weight Loss A personalized nutrition plan ensures youre fueling your body with the right nutrients

Your doctor should monitor your TSH and free T4 levels before starting treatment and 68 weeks after your dose stabilizes